Ironwood shares edge up as June debt test draws investor attention
Ironwood Pharmaceuticals stock was up 0.9% at $3.43 in Friday morning trading, putting the company’s market cap around $572 million. Investors turned more attention to the bowel-disorder drugmaker after management took part in a Jefferies healthcare event and with a key debt maturity approaching in mid-June. Ironwood’s 2026 outlook hinges less on daily share prices and more on LINZESS cash flow covering debt and paying for another trial. The Boston drugmaker’s execs appeared at a Jefferies Global Healthcare Conference fireside chat on June 4, the last scheduled investor event before its notes come due.